Park Aerospace Corp. Announces Ground-Breaking for Major Expansion of Its Manufacturing and Development Facilities in Newton, Kansas

NEWTON, Kan., Aug. 19, 2019 (GLOBE NEWSWIRE) — Park Aerospace Corp. (NYSE-PKE) announced that, on August 15, 2019, the Company celebrated the official ground-breaking for the major expansion of its manufacturing and development facilities located at the Newton City-County Airport… Read morePark Aerospace Corp. Announces Ground-Breaking for Major Expansion of Its Manufacturing and Development Facilities in Newton, Kansas

T-Rex makes the Inc. 5000 List for 4th Year as a Fastest Growing Company Standing out Among Mid-Tier Government Sector Firms

GREENBELT, Md., Aug. 19, 2019 /PRNewswire/ — This week Inc. 5000 ranked the country’s top 5000 fastest-growing private companies and T-Rex is proud to be ranked at #270. T-Rex is the #1 fastest growing company among mid-tier Government Services Sector firms with… Read moreT-Rex makes the Inc. 5000 List for 4th Year as a Fastest Growing Company Standing out Among Mid-Tier Government Sector Firms

The global sports sunglasses market at a CAGR of about 4% during the forecast period

NEW YORK, Aug. 19, 2019 /PRNewswire/ — Global Sports Sunglasses Market: About this market Sports sunglasses help athletes and sportspersons enhance their visibility in bright conditions, thereby driving their performance. This sports sunglasses market analysis considers sales from both offline… Read moreThe global sports sunglasses market at a CAGR of about 4% during the forecast period

The global neurodiagnostic and monitoring devices market at a CAGR of over 8% during the forecast period

NEW YORK, Aug. 19, 2019 /PRNewswire/ — Global Neurodiagnostic and Monitoring Devices Market: About this market Neurodiagnostic and monitoring devices are medical devices that aid in the diagnosis and monitoring of neurological disorders. This neurodiagnostic and monitoring devices market analysis… Read moreThe global neurodiagnostic and monitoring devices market at a CAGR of over 8% during the forecast period

Dave Matthews to Perform Exclusive Acoustic Set in Los Angeles for SiriusXM and Pandora on September 11

NEW YORK, Aug. 19, 2019 /PRNewswire/ — SiriusXM announced today that Dave Matthews will perform an intimate invitation-only acoustic set for SiriusXM subscribers on Wednesday, September 11 at “The Garage” performance space in SiriusXM’s newly expanded LA studios. Matthews will also… Read moreDave Matthews to Perform Exclusive Acoustic Set in Los Angeles for SiriusXM and Pandora on September 11

Global Oil and Gas Mobility Market 2019-2025: Market is Projected to Grow by US$44.5 Billion, Guided by a Compounded Growth of 21.9%

DUBLIN, Aug. 19, 2019 /PRNewswire/ — The “Oil and Gas Mobility – Market Analysis, Trends, and Forecasts” report has been added to ResearchAndMarkets.com’s offering. Oil and Gas Mobility market worldwide is projected to grow by US$44.5 Billion, guided by a… Read moreGlobal Oil and Gas Mobility Market 2019-2025: Market is Projected to Grow by US$44.5 Billion, Guided by a Compounded Growth of 21.9%

/R E P R I S E — MISE À JOUR – Avis aux médias – Convocation – Annonce concernant le transport en commun de la ville de Québec/

Veuillez prendre note que le lieu de l’événement a changé. QUÉBEC, le 18 août 2019 /CNW Telbec/ – Le ministre des Transports et ministre responsable de la région de l’Estrie, M. François Bonnardel, et le maire de la ville de Québec,… Read more/R E P R I S E — MISE À JOUR – Avis aux médias – Convocation – Annonce concernant le transport en commun de la ville de Québec/

Vascular Therapies Completes Enrollment in the ACCESS Study, a U.S. Phase III Clinical Trial

CRESSKILL, N.J., Aug. 19, 2019 /PRNewswire/ — Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of enrollment in its US Phase III prospective randomized, multicenter, clinical study (ACCESS Trial). The… Read moreVascular Therapies Completes Enrollment in the ACCESS Study, a U.S. Phase III Clinical Trial